The HLA Typing Market is projected to grow at a compound annual growth rate (CAGR) of 5.6% from 2022 to 2029, with an anticipated market value of $1.90 billion by the end of 2029. This growth is attributed to the increasing incidence of organ failures and advancements in HLA typing technologies.
Request For Sample Report: https://www.meticulousresearch.com/request-sample-report/cp_id=5311?
Critical Role of HLA Genes
HLA genes are expressed by nearly all nucleated cells and play a vital role in the body’s ability to accept or reject transplanted organs. Accurate HLA matching between donors and recipients is essential for successful organ transplantation, driving the demand for precise HLA typing.
Factors Contributing to Organ Failures
Chronic health conditions, including diabetes, high blood pressure, metabolic syndrome, and chronic kidney disease (CKD), are significant contributors to organ failures. In 2021, the CDC noted that about 37 million Americans had CKD, which heightens the risk of organ failure and escalates the demand for transplantation services.
Organ Transplant Procedures Influence Market Growth
The rise in organ transplant procedures, along with better success rates and improved post-transplant outcomes, continues to foster growth in the HLA typing market. The technological advancements in HLA typing solutions further propel this expansion.
Evolution of HLA Typing Technologies
Early HLA typing methods relied on serological assays, which were limited in resolution and faced challenges due to polyclonal sera. The introduction of Polymerase Chain Reaction (PCR) technology marked a significant improvement in HLA genotyping accuracy, although it had difficulties in distinguishing between alleles. More sophisticated technologies, such as Sanger sequencing, and the introduction of Next Generation Sequencing (NGS) and third-generation sequencing, have transformed HLA typing.